Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab long-term safety after feeder trials (Japan)
jRCT2080225185Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label trial of aducanumab in Alzheimer's disease (AD) (2 arms), sponsored by Biogen. Primary endpoint: Primary safety and tolerability over 100 weeks. Started May 2020; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080225185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225185.